Stem Cell Thomas Biotechnology (Chengdu) Co.,Ltd
Established in 2018 and headquartered at the Tri-Medicine Innovation Center in Chengdu Medical City, Stem Cell Thomas Biotech is a high-tech enterprise integrating cutting-edge biomedical research with clinical translation. With a total investment of RMB 200 million and an operating area of approximately 5,000 m², the company pioneers innovative applications in life sciences.

Led by its Chief Scientist, Professor Thomas Südhof (2013 Nobel Laureate in Physiology or Medicine), Stem Cell Thomas boasts a prestigious Expert Committee comprising two Nobel Laureates, academicians, and globally renowned “Thousand Talents Plan” scholars. Grounded in advanced global biotechnology, the company focuses on cellular biology R&D, specializing in autologous stem cells and immune cell technologies for translation, application, and commercialization.

The company’s state-of-the-art biomedical laboratory—a government-approved regional key project—is designed, constructed, and operated to exceed international standards. Strictly compliant with AABB, GMP, and Class B+A cleanroom classifications, it holds national accreditation for cell production, quality control, and dual certifications as a Regional Cell Preparation Center and Cell Storage Center.

Stem Cell Thomas is accredited by China’s National Standardization Committee for drafting stem/immune cell production and quality control standards, including co-authoring *T/CRHA003-2021: General Requirements for Human-Derived Stem Cell Testing*.

With a comprehensive proprietary IP portfolio, the company’s patented technologies address critical gaps in regenerative medicine, anti-aging rehabilitation, immune cell-based cancer prevention/therapy, and medical aesthetics. It offers elite clients personalized anti-aging management services integrating genetic testing, cell banking, regenerative medicine, and immune cell-based cancer prevention.